ArticleFrontiers in immunology2017
Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis.
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.Frontiers in immunology · 2022Pooled it
- Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells.Journal of cellular and molecular medicine · 2021Trial
- The rise of exosome-mediated mechanisms in MSC therapy.Journal of translational medicine · 2025Article
- Interleukin-1 receptor antagonist overexpression in mesenchymal stem cells improves hemorrhagic cystitis outcomes via HtrA serine peptidase 3.Stem cell research & therapy · 2025Article
- Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease.Stem cells (Dayton, Ohio) · 2024Article
- Better clinical outcomes and lower triggering of inflammatory cytokines for allogeneic hematopoietic cell transplant recipients treated in home care versus hospital isolation - the Karolinska experience.Frontiers in immunology · 2024Review
- Regulation of Immune Checkpoint Antigen CD276 (B7-H3) on Human Placenta-Derived Mesenchymal Stromal Cells in GMP-Compliant Cell Culture Media.International journal of molecular sciences · 2023Article
- A review of the application of mesenchymal stem cells in the field of hematopoietic stem cell transplantation.European journal of medical research · 2023Review
- Cell-Based Therapy Approaches in Treatment of Non-obstructive Azoospermia.Reproductive sciences (Thousand Oaks, Calif.) · 2023Review
- Infusion of Some but Not All Types of Human Perinatal Stromal Cells Prevent Organ Fibrosis in a Humanized Graft versus Host Disease Murine Model.Biomedicines · 2023Article
- Novel therapies for graft versus host disease with a focus on cell therapies.Frontiers in immunology · 2023Review
- Mesenchymal stroma/stem cells: Haematologists' friend or foe?British journal of haematology · 2022Review
- Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products.Stem cells translational medicine · 2022Article
- In-cytoplasm mitochondrial transplantation for mesenchymal stem cells engineering and tissue regeneration.Bioengineering & translational medicine · 2022Article
- Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review.Frontiers in immunology · 2022Review
- Mesenchymal stem cells: ideal seeds for treating diseases.Human cell · 2021Review
- An Intelligent Clinical Decision Support System for Predicting Acute Graft-versus-host Disease (aGvHD) following Allogeneic Hematopoietic Stem Cell Transplantation.Journal of biomedical physics & engineering · 2021Article
- Mesenchymal stromal cell delivery via an ex vivo bioreactor preclinical test system attenuates clot formation for intravascular application.Stem cells translational medicine · 2021Article
- Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy.Stem cell reviews and reports · 2021Article
- Mesenchymal stromal cells in hematopoietic cell transplantation.Blood advances · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute graft-versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT). DSCs are more immunosuppressive than MSCs. We assessed adverse events and safety using DSCs among 44 treated patients and 40 controls. The median dose of infused cells was 1.5 (range 0.9-2.9) × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.